Drug Profile
Tesnatilimab - Janssen Biotech
Alternative Names: Anti-NKG2D; IPH-2301; IPH-23XX; JNJ 4500; JNJ-64304500; JNJ-64304500 - Janssen Biotech; NN-8555; NNC-0142-0000-0002; NNC-0142-0002Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Innate Pharma; Novo Nordisk
- Developer Janssen Biotech; Janssen Research & Development; Novo Nordisk
- Class Anti-inflammatories; Antirheumatics; Monoclonal antibodies
- Mechanism of Action NK cell lectin-like-receptor subfamily K antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Crohn's disease
- Discontinued Inflammation
Most Recent Events
- 25 Sep 2022 Pharmacokinetics and adverse events data from a phase IIb TRIDENT in Crohn's disease presented at the American College of Clinical Pharmacology Annual Meeting (ACCP-2022)
- 24 Jan 2022 Janssen Research & Development completes a phase II trial in Crohn's disease in the US, France, Hungary, Germany, Japan, Russia, Poland, Ukraine, Romania, South Korea, Bulgaria, Belgium, the UK and Canada (NCT02877134)
- 15 Jun 2021 Janssen Research & Development completes a phase I trial for Crohn's-disease (In volunteers) in USA (SC) (NCT04667052)